Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging for clarity on how Omnicell’s medication-dispensing platforms boost hospital margins—or when its executives last traded shares—means wading through dense disclosures. If you have ever searched “Omnicell insider trading Form 4 transactions” or “Omnicell annual report 10-K simplified,” you know the challenge. Reimbursement nuances, FDA device updates, and SaaS revenue recognition rules hide in hundreds of pages. Investors need “Omnicell SEC filings explained simply,” not another data dump.
Stock Titan solves that problem. Our AI parses every Omnicell quarterly earnings report 10-Q filing, urgent 8-K material events, and even footnotes your accountant flagged. The platform delivers:
- Concise AI-powered summaries for understanding Omnicell SEC documents with AI
- Real-time alerts on Omnicell Form 4 insider transactions—yes, the moment they hit EDGAR
- Side-by-side comparisons that turn Omnicell earnings report filing analysis into a two-minute read
- Instant links to Omnicell proxy statement executive compensation tables and voting matters
Want practical insights? Our dashboards surface which hospital automation segment drives revenue growth in the 10-K, flag R&D spikes tied to next-gen IV compounding, and spotlight Omnicell executive stock transactions Form 4 before contract announcements. You’ll also see Omnicell 8-K material events explained, from FDA clearances to cybersecurity notices. In short, we merge every filing type—10-K, 10-Q, 8-K, Form 4, DEF 14A—into one interface so you can act faster and smarter.
Omnicell, Inc.'s Executive Vice President and Chief Legal/Administrative Officer reported routine share movements. On December 15, 2025, 224 shares of common stock were withheld to cover taxes due on the vesting of restricted stock units. On December 16, 2025, the executive sold 278 shares of Omnicell common stock at an exact price of $43.30 per share.
The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After these transactions, the executive beneficially owned 97,780 shares of Omnicell common stock, all held directly.
Omnicell, Inc. reported an insider equity transaction by its Chairman, President and CEO and director, Randall Lipps. On 12/15/2025, the company withheld 1,147 shares of common stock at $43.27 per share to cover taxes due upon the vesting of restricted stock units, which is a non-open-market transaction. After this tax withholding, Mr. Lipps beneficially owned 385,501 shares of Omnicell common stock directly, plus 355,861 shares held in a trust with his wife and 8,051 shares held in trust for the benefit of his children.
Omnicell, Inc. (OMCL)226 shares of common stock were withheld to cover taxes due in connection with the vesting of restricted stock units at a price of $35.12 per share. After this tax withholding, Nutt directly owns 17,342 shares of Omnicell common stock. This is an administrative equity event tied to compensation rather than an open‑market buy or sell.
Omnicell, Inc. reported an insider share disposition by its Chairman, President and CEO, Randall A. Lipps. On 11/15/2025, Lipps disposed of 8,437 shares of Omnicell common stock at a price of $35.12 per share, coded as an "F" transaction, which indicates shares were withheld to cover taxes related to vesting restricted stock units. Following this transaction, he directly owned 386,648 shares. He also held 355,861 shares in a trust with his wife and 8,051 shares in a trust for the benefit of his children.
Omnicell, Inc. executive reports routine share withholding for taxes. The company’s EVP and Chief Operating Officer reported the disposition of 4,095 shares of Omnicell common stock on 11/15/2025 at a price of $35.12 per share, coded as an "F" transaction, which indicates shares were withheld to cover taxes due on vesting of restricted stock units.
After this tax withholding, the executive beneficially owns 87,193 shares of Omnicell common stock. This balance includes an adjustment for 359 shares purchased under Omnicell’s Employee Stock Purchase Plan on 8/15/2025, as noted in the footnotes.
Omnicell, Inc. (OMCL) reported an equity award to its Executive Vice President & Chief Financial Officer, H. Baird Radford III, on a Form 4. On 11/15/2025, he received 32,932 shares of Omnicell common stock in the form of restricted stock units granted under the company’s equity incentive plan at a stated price of $0 per share, reflecting a stock-based award rather than a cash purchase. After this grant, he beneficially owns 32,932 shares directly. The award vests over time: 25% of the shares are scheduled to vest on November 15, 2026, and the remaining 75% vest in equal quarterly installments over three years on 2/15, 5/15, 8/15, and 11/15, aligning his compensation with longer-term company performance.
Omnicell, Inc. (OMCL)
Omnicell, Inc. executive reports routine stock transactions. The EVP and Chief Legal/Administrative Officer reported two transactions in Omnicell common stock. On 11/15/2025, 2,792 shares were withheld to cover taxes due on vesting of restricted stock units at a price of $35.12 per share, leaving 107,861 shares beneficially owned. On 11/17/2025, the executive sold 3,473 shares at an exact price of $34.90 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, resulting in 104,388 shares beneficially owned after the sale. The filing is made by one reporting person.
Omnicell reported Q3 2025 results, with total revenue of $310.6 million, up from $282.4 million a year ago. Product revenue was $177.5 million and service revenue was $133.1 million. Net income was $5.5 million, or $0.12 per diluted share, versus $8.6 million, or $0.19, last year as operating expenses rose.
For the first nine months, revenue reached $870.9 million with net income of $4.1 million. Cash from operations was $96.9 million. The company ended the quarter with $180.1 million in cash and cash equivalents. Omnicell repaid the remaining $175.0 million principal of its 0.25% convertible notes due 2025 and had $167.3 million (net) outstanding on the 1.00% notes due 2029. Deferred revenues were $245.5 million, including $178.8 million current.
Stockholders’ equity was $1.22 billion. The company repurchased common stock totaling $77.6 million year‑to‑date, and shares outstanding were 44,876,522 as of October 29, 2025.
Omnicell, Inc. furnished an update on performance, announcing third-quarter 2025 financial results and an update to full-year 2025 guidance via a press release. The company provided the details in Exhibit 99.1, referenced under Item 2.02 of the report. The information in Item 2.02 and Exhibit 99.1 is being furnished and not filed under the Exchange Act.
FAQ
What is the current stock price of Omnicell Com (OMCL)?
What is the market cap of Omnicell Com (OMCL)?
